A rare cutaneous adverse effect secondary to cabozantinib therapy.
Oxf Med Case Reports
; 2018(12): omy105, 2018 Dec.
Article
en En
| MEDLINE
| ID: mdl-30487990
ABSTRACT
Cabozantinib is a tyrosine kinase inhibitor which is increasingly being used for the treatment of metastatic renal cell cancer. Skin toxicity such as palmar-plantar erythrodysesthesia is not uncommon with such agents. However, bullous skin reactions are not common and we report the case of a patient with metastatic renal cell cancer who experienced such cutaneous toxicity.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Oxf Med Case Reports
Año:
2018
Tipo del documento:
Article
País de afiliación:
Reino Unido